BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;9:CD012143. [PMID: 28922704 DOI: 10.1002/14651858.CD012143.pub3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Pericot-Valverde I, Heo M, Akiyama MJ, Norton BL, Agyemang L, Niu J, Litwin AH. Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial. BMC Infect Dis 2020;20:928. [PMID: 33276738 DOI: 10.1186/s12879-020-05667-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Calvaruso V, Petta S, Cacciola I, Cabibbo G, Cartabellotta F, Distefano M, Scifo G, Di Rosolini MA, Russello M, Prestileo T, Madonia S, Malizia G, Montineri A, Digiacomo A, Licata A, Benanti F, Bertino G, Enea M, Battaglia S, Squadrito G, Raimondo G, Cammà C, Craxì A, Di Marco V; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. J Viral Hepat 2021;28:1190-9. [PMID: 33896097 DOI: 10.1111/jvh.13523] [Reference Citation Analysis]
3 Bjelakovic M, Nikolova D, Bjelakovic G, Gluud C. Vitamin D supplementation for chronic liver diseases in adults. Cochrane Database Syst Rev 2021;8:CD011564. [PMID: 34431511 DOI: 10.1002/14651858.CD011564.pub3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 El-yazbi AF, Elashkar NE, Abdel-hay KM, Ahmed HM, Talaat W. Eco-friendly analytical methods for the determination of compounds with disparate spectral overlapping: application to antiviral formulation of sofosbuvir and velpatasvir. J Anal Sci Technol 2021;12. [DOI: 10.1186/s40543-021-00257-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Nicastro E, Norsa L, Di Giorgio A, Indolfi G, D'Antiga L. Breakthroughs and challenges in the management of pediatric viral hepatitis. World J Gastroenterol 2021; 27(20): 2474-2494 [PMID: 34092970 DOI: 10.3748/wjg.v27.i20.2474] [Reference Citation Analysis]
6 González-Corvillo C, Beneyto I, Sánchez-Fructuoso A, Perelló M, Alonso A, Mazuecos A, Jiménez C, Zárraga S, Paul J, Lauzurica R, Hernández D, Guirado L, Franco A, Ruiz JC, Llorente S, Crespo M, Rodríguez-Benot A, de Gracia Guindo MDC, Díaz-Corte C, Gentil MÁ. Direct-acting Antivirals for the Treatment of Kidney Transplant Patients With Chronic Hepatitis C Virus Infection in Spain: A Long-term Prospective Observational Study. Transplant Direct 2019;5:e510. [PMID: 32095505 DOI: 10.1097/TXD.0000000000000954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Liang N, Kong Z, Lu CL, Ma SS, Li YQ, Nikolova D, Jakobsen JC, Gluud C, Liu JP. Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B. Cochrane Database Syst Rev 2019;6:CD013106. [PMID: 31232459 DOI: 10.1002/14651858.CD013106.pub2] [Reference Citation Analysis]
8 Margusino-Framiñán L, Cid-Silva P, Rotea-Salvo S, Mena-de-Cea Á, Suárez-López F, Vázquez-Rodríguez P, Delgado-Blanco M, Sanclaudio-Luhia AI, Martín-Herranz I, Castro-Iglesias Á. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. Eur J Hosp Pharm 2020;27:e41-7. [PMID: 32296504 DOI: 10.1136/ejhpharm-2019-002060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Leoni MC, Ustianowski A, Farooq H, Arends JE. HIV, HCV and HBV: A Review of Parallels and Differences. Infect Dis Ther 2018;7:407-19. [PMID: 30182282 DOI: 10.1007/s40121-018-0210-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
10 Singh S, Nautiyal A, Loke YK. Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis. Frontline Gastroenterol 2018;9:262-70. [PMID: 30245788 DOI: 10.1136/flgastro-2018-101017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
11 Simonetti RG, Perricone G, Nikolova D, Bjelakovic G, Gluud C. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis. Cochrane Database Syst Rev 2019;6:CD004039. [PMID: 31251387 DOI: 10.1002/14651858.CD004039.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Reference Citation Analysis]
13 Krassenburg LAP, Zanjir WR, Georgie F, Stotland E, Janssen HLA, Hansen BE, Feld JJ. Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. Clin Infect Dis 2021;72:780-6. [PMID: 32052014 DOI: 10.1093/cid/ciaa144] [Reference Citation Analysis]
14 Imperatore N, Castiglione F, Rispo A, Sessa A, Caporaso N, Morisco F. Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases. Front Pharmacol 2017;8:867. [PMID: 29209223 DOI: 10.3389/fphar.2017.00867] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
15 Marcus JL, Hurley LB, Chamberland S, Champsi JH, Korn DG, Lai JB, Lam JO, Quesenberry CP Jr, Ready J, Saxena V, Seo SI, Witt DJ, Silverberg MJ. Life Expectancy of Insured People With and Without Hepatitis C Virus Infection, 2007-2017. Open Forum Infect Dis 2020;7:ofaa044. [PMID: 32128339 DOI: 10.1093/ofid/ofaa044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Liang N, Kong Z, Ma SS, Lu CL, Yang M, Feng LD, Shen C, Diao RH, Cui LJ, Lu XY, Nikolova D, Jakobsen JC, Gluud C, Liu JP. Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B. Cochrane Database Syst Rev 2019;4:CD013089. [PMID: 30941748 DOI: 10.1002/14651858.CD013089.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Kong Z, Liang N, Yang GL, Zhang Z, Liu Y, Yang Y, Liu YX, Wang QG, Zhang F, Zhang HY, Nikolova D, Jakobsen JC, Gluud C, Liu JP. Acupuncture for chronic hepatitis B. Cochrane Database Syst Rev 2019;8:CD013107. [PMID: 31436846 DOI: 10.1002/14651858.CD013107.pub2] [Reference Citation Analysis]
18 Suenaga R, Suka M, Hirao T, Hidaka I, Sakaida I, Ishida H. Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages. PLoS One 2021;16:e0248748. [PMID: 33793594 DOI: 10.1371/journal.pone.0248748] [Reference Citation Analysis]
19 Haley DF, Edmonds A, Ramirez C, French AL, Tien P, Thio CL, Witt MD, Seaberg EC, Plankey MW, Cohen MH, Adimora AA. Direct-Acting Antiviral Hepatitis C Treatment Cascade and Barriers to Treatment Initiation Among US Men and Women With and Without HIV. J Infect Dis 2021;223:2136-44. [PMID: 33141170 DOI: 10.1093/infdis/jiaa686] [Reference Citation Analysis]
20 Jakobsen JC, Ovesen C, Winkel P, Hilden J, Gluud C, Wetterslev J. Power estimations for non-primary outcomes in randomised clinical trials. BMJ Open 2019;9:e027092. [PMID: 31175197 DOI: 10.1136/bmjopen-2018-027092] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
21 Parrish NF, Feurer ID, Matsuoka LK, Rega SA, Perri R, Alexopoulos SP. The Changing Face of Liver Transplantation in the United States: The Effect of HCV Antiviral Eras on Transplantation Trends and Outcomes. Transplant Direct 2019;5:e427. [PMID: 30882032 DOI: 10.1097/TXD.0000000000000866] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
22 Kong Z, Liang N, Yang GL, Zhang Z, Liu Y, Li J, Liu X, Liang S, Nikolova D, Jakobsen JC, Gluud C, Liu JP. Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B. Cochrane Database Syst Rev 2019;2019. [PMID: 31697415 DOI: 10.1002/14651858.CD013090.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
24 Bjelakovic G, Nikolova D, Bjelakovic M, Gluud C. Vitamin D supplementation for chronic liver diseases in adults. Cochrane Database Syst Rev. 2017;11:CD011564. [PMID: 29099543 DOI: 10.1002/14651858.cd011564.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
25 Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal. 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
26 McGlynn EA, Adams JL, Kramer J, Sahota AK, Silverberg MJ, Shenkman E, Nelson DR. Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C. JAMA Netw Open 2019;2:e194765. [PMID: 31173117 DOI: 10.1001/jamanetworkopen.2019.4765] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
27 Ioannou GN, Green PK, Berry K, Graf SA. Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting Antivirals. Hepatol Commun 2019;3:1124-36. [PMID: 31388632 DOI: 10.1002/hep4.1389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]